Overview
Overview Executive Committee Supervisory Board Locations
Overview Satraplatin Kinase Inhibitors
Stock Major Shareholdings Key Figures Financial Reports SEC Filings Corporate Governance Analyst Coverage Shareholder´s Meeting Webcasts Information Request
Press Releases Contact Information
Working for GPC Biotech Germany USA
GPC Biotech Shareholders Approve Merger into New Agennix AG New Data from Satraplatin Phase 3 Trial in Second-Line Castrate-Refractory Prostate Cancer Presented at 2009 ASCO Annual Meeting Conference Call on Q1 2009 Financial Results GPC Biotech Reports Financial Results for First Quarter 2009 GPC Biotech Announces Two Upcoming Corporate Events Annual General Meeting: Information and Documents New Pre-Clinical Data on RGB-286638 Multi-Targeted Kinase Inhibitor Presented at AACR GPC Biotech Reports Financial Results for Fiscal Year 2008 GPC Biotech AG Announces Dismissal of U.S. Class Action Lawsuit Safety and Overall Survival Data in Docetaxel-Refractory Patients Enrolled in the Satraplatin SPARC Trial Being Presented at 2009 ASCO Genitourinary Cancers Symposium GPC Biotech and Agennix Announce Proposed Merger GPC Biotech Opens Enrollment in Phase 1 Trial Evaluating RGB-286638 Multi-Targeted Protein Kinase Inhibitor in Patients with Advanced Solid Tumors